HILS vs. CVKD, EFTR, KTTA, SHPH, TFFP, ENTO, NBY, PULM, FWBI, and HEPA
Should you be buying Hillstream BioPharma stock or one of its competitors? The main competitors of Hillstream BioPharma include Cadrenal Therapeutics (CVKD), eFFECTOR Therapeutics (EFTR), Pasithea Therapeutics (KTTA), Shuttle Pharmaceuticals (SHPH), TFF Pharmaceuticals (TFFP), Entero Therapeutics (ENTO), NovaBay Pharmaceuticals (NBY), Pulmatrix (PULM), First Wave BioPharma (FWBI), and Hepion Pharmaceuticals (HEPA). These companies are all part of the "pharmaceutical preparations" industry.
Hillstream BioPharma (NASDAQ:HILS) and Cadrenal Therapeutics (NASDAQ:CVKD) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, media sentiment, analyst recommendations, community ranking, profitability, risk, valuation, institutional ownership and dividends.
In the previous week, Cadrenal Therapeutics had 4 more articles in the media than Hillstream BioPharma. MarketBeat recorded 4 mentions for Cadrenal Therapeutics and 0 mentions for Hillstream BioPharma. Cadrenal Therapeutics' average media sentiment score of 1.19 beat Hillstream BioPharma's score of 0.00 indicating that Cadrenal Therapeutics is being referred to more favorably in the news media.
Hillstream BioPharma is trading at a lower price-to-earnings ratio than Cadrenal Therapeutics, indicating that it is currently the more affordable of the two stocks.
Cadrenal Therapeutics' return on equity of -75.11% beat Hillstream BioPharma's return on equity.
Hillstream BioPharma has a beta of 3.08, suggesting that its stock price is 208% more volatile than the S&P 500. Comparatively, Cadrenal Therapeutics has a beta of 1.64, suggesting that its stock price is 64% more volatile than the S&P 500.
13.4% of Hillstream BioPharma shares are owned by institutional investors. Comparatively, 7.9% of Cadrenal Therapeutics shares are owned by institutional investors. 30.2% of Hillstream BioPharma shares are owned by company insiders. Comparatively, 58.1% of Cadrenal Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Cadrenal Therapeutics has a consensus target price of $3.50, indicating a potential upside of 771.51%. Given Cadrenal Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Cadrenal Therapeutics is more favorable than Hillstream BioPharma.
Cadrenal Therapeutics received 3 more outperform votes than Hillstream BioPharma when rated by MarketBeat users. Likewise, 100.00% of users gave Cadrenal Therapeutics an outperform vote while only 50.00% of users gave Hillstream BioPharma an outperform vote.
Summary
Cadrenal Therapeutics beats Hillstream BioPharma on 13 of the 15 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding HILS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Hillstream BioPharma Competitors List
Related Companies and Tools
